Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.110
-0.660 (-23.83%)
At close: Jun 17, 2026, 4:00 PM EDT
2.330
+0.220 (10.43%)
After-hours: Jun 17, 2026, 7:58 PM EDT
Spero Therapeutics Revenue
Spero Therapeutics had revenue of $258.00K in the quarter ending March 31, 2026, a decrease of -95.61%. This brings the company's revenue in the last twelve months to $61.19M, up 37.24% year-over-year. In the year 2025, Spero Therapeutics had annual revenue of $66.80M with 39.24% growth.
Revenue (ttm)
$61.19M
Revenue Growth
+37.24%
P/S Ratio
2.00
Revenue / Employee
$2,447,440
Employees
25
Market Cap
122.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66.80M | 18.83M | 39.24% |
| Dec 31, 2024 | 47.98M | -55.80M | -53.77% |
| Dec 31, 2023 | 103.78M | 50.27M | 93.95% |
| Dec 31, 2022 | 53.51M | 35.25M | 193.10% |
| Dec 31, 2021 | 18.26M | 8.93M | 95.67% |
| Dec 31, 2020 | 9.33M | -8.82M | -48.59% |
| Dec 31, 2019 | 18.15M | 14.18M | 357.56% |
| Dec 31, 2018 | 3.97M | 1.99M | 100.40% |
| Dec 31, 2017 | 1.98M | 1.64M | 490.75% |
| Dec 31, 2016 | 335.00K | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 76.38M |
| Alector | 18.42M |
| ProQR Therapeutics | 15.73M |
| Caribou Biosciences | 11.20M |
| Innate Pharma | 10.57M |
| Korro Bio | 3.84M |
SPRO News
- 13 hours ago - Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) - GlobeNewsWire
- 14 hours ago - GSK, Spero Therapeutics announce FDA approval of Utebzi - TheFly
- 5 weeks ago - Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Spero Therapeutics Earnings release: Q1 2026 - Filings
- 5 weeks ago - Spero Therapeutics Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - GlobeNewsWire
- 7 weeks ago - Spero Therapeutics Proxy statement: Proxy filing - Filings
- 7 weeks ago - Spero Therapeutics Proxy statement: Proxy filing - Filings